Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. - Dapagliflozin is identified as cost-effective when provided in addition to standard of care to patients who have heart failure with reduced ejection fraction (HFrEF) with and without diabetes. Researchers recommend increasing therapy rates among these patients given evidence of clinical benefit and economic value.

• A Markov model based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure population was used in this economic evaluation.

• An incremental cost-effectiveness ratio of $83,650 per quality-adjusted life-year gained was recorded in correlation with dapagliflozin indicating its intermediate value according to American College of Cardiology/American Heart Association benchmarks.

• Subgroups with and without diabetes and those with more or less impaired health status due to heart failure showed similar cost-effectiveness of dapagliflozin.